Q4 2023 13F Holders as of 12/31/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
66.6M
-
Number of holders
-
53
-
Total 13F shares, excl. options
-
5.28M
-
Shares change
-
-159K
-
Total reported value, excl. options
-
$7.81M
-
Value change
-
-$209K
-
Put/Call ratio
-
1.58
-
Number of buys
-
13
-
Number of sells
-
-21
-
Price
-
$1.48
Significant Holders of Cardiff Oncology, Inc. - Common Stock (CRDF) as of Q4 2023
66 filings reported holding CRDF - Cardiff Oncology, Inc. - Common Stock as of Q4 2023.
Cardiff Oncology, Inc. - Common Stock (CRDF) has 53 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.28M shares
of 66.6M outstanding shares and own 7.93% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (1.91M shares), Laurion Capital Management LP (722K shares), BlackRock Inc. (716K shares), GEODE CAPITAL MANAGEMENT, LLC (424K shares), MAI Capital Management (379K shares), STATE STREET CORP (140K shares), BLAIR WILLIAM & CO/IL (130K shares), RENAISSANCE TECHNOLOGIES LLC (116K shares), NORTHERN TRUST CORP (71.4K shares), and ELKHORN PARTNERS LIMITED PARTNERSHIP (65.5K shares).
This table shows the top 53 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.